Furthermore, TP53 and CDKN2A mutations in other squamous cell carcinomas such as NSCLC (60) and HNSCC (61) correlates with response to immune checkpoint inhibitors. This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.